Midodrine Hcl
Brand names: Midodrine Hcl
At a glance
- Medicare prescriptions, 2024
- 1,073,485
- Medicare drug cost
- $68.1M
- Average cost per prescription
- $63.44
- Clinicians who prescribed it
- 37,990
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Midodrine hydrochloride tablets, USP are indicated for the treatment of symptomatic orthostatic hypotension (OH). Because midodrine hydrochloride tablets, USP can cause marked elevation of supine blood pressure (BP > 200 mmHg systolic), it should be used in patients whose lives are considerably impaired despite standard clinical care, including non-pharmacologic treatment (such as support stockings), fluid expansion, and lifestyle alterations. The indication is based on midodrine hydrochloride tablets, USP effect on increases in 1-minute standing systolic blood pressure, a surrogate marker considered likely to correspond to a clinical benefit. At present, however, clinical benefits of midodrine hydrochloride tablets, USP principally improved ability to perform life activities, have not been established. Further clinical trials are underway to verify and describe the clinical benefits of midodrine hydrochloride tablets, USP. After initiation of treatment, midodrine hydrochloride tablets, USP should be continued only for patients who report significant symptomatic improvement.
From the FDA-approved prescribing information (label dated August 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Internal Medicine 27.1%
- Family Medicine 18.3%
- Nurse Practitioners 17.6%
- Cardiology 10.3%
- Nephrology (Kidney) 6.9%
- Geriatric Medicine 3.7%
- Interventional Cardiology 3.2%
- Physician Assistants 3.1%
- Neurology 2.3%
- Hospitalist 1.6%
- Cardiac Electrophysiology 1.3%
- General Practice 1.0%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 75% from 2019 to 2024.
Biggest change by state since 2019
- Arkansas +121%
- Washington +99%
- Florida +97%
- Alabama +91%
- South Carolina +90%
- Oregon (smallest change) +46%
- Tennessee (smallest change) +53%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 2 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Par Health USA, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 2.5 mg | white round tablet, 6 mm, scored to split in 2 | P 814 |
| 5 mg | white round tablet, 8 mm, scored to split in 2 | P 849 |
| 10 mg | white round tablet, 10 mm, scored to split in 2 | P 874 |
Rebel Distributors Corp
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | blue round tablet, 7 mm, scored to split in 2 | E 149 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
1 recall since 2020
- Feb 2026 · The Harvard Drug Group LLC · Class II
Defective container; inadequately sealed blister packaging.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.